Apricus Biosciences (APRI) Posts Q4 Loss of 40c/Share

Apricus Biosciences (NASDAQ: APRI) reported Q4 EPS of ($0.40), $0.28 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $670 thousand.

2015 Financial Outlook

In 2015, Apricus expects to generate cash from milestone payments and royalty revenues from partner sales of Vitaros. Apricus will also continue to pursue out-license opportunities for Vitaros in Asia Pacific and Latin America. Apricus' expenditures will include costs to generate stability data for room temperature Vitaros, for activities associated with supporting commercialization and launches of Vitaros in Europe, and clinical development of fispemifene and RayVa. Apricus believes its current cash will support its operating plan through 2015.

For earnings history and earnings-related data on Apricus Biosciences (APRI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c